{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T11:52:34Z","timestamp":1792324354022,"version":"4.4.0"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.ejps.2015.12.018","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T21:01:33Z","timestamp":1450386093000},"page":"88-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":148,"special_numbering":"C","title":["Pharmaceutical excipients \u2014 quality, regulatory and biopharmaceutical considerations"],"prefix":"10.1016","volume":"87","author":[{"given":"David P.","family":"Elder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Kuentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2015.12.018_bb0005","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1002\/jps.2600690613","article-title":"Extended Hildebrand approach. Solubility of caffeine in dioxane\u2013water mixtures","volume":"69","author":"Adjei","year":"1980","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.12.018_bb0010","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1023\/A:1016256619309","article-title":"The effect of different concentrations of mannitol in solution on small intestinal transit: implications for drug absorption","volume":"12","author":"Adkin","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2015.12.018_bb0015","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1023\/B:PHAM.0000008043.71001.43","article-title":"Development of a 7-day, 96-well Caco-2 permeability assay with high-throughput direct UV compound analysis","volume":"20","author":"Alsenz","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2015.12.018_bb0020","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1002\/jps.20814","article-title":"Development of a partially automated solubility screening (PASS) assay for early drug development","volume":"96","author":"Alsenz","year":"2007","journal-title":"J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejps.2015.12.018_bb9025","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1023\/A:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2015.12.018_bb0025","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1021\/cg3002948","article-title":"Polymorphs, salts and cocrystals: what's in a name?","volume":"12","author":"Atipamula","year":"2012","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejps.2015.12.018_bb0030","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1007\/s11095-006-9169-0","article-title":"Solubility-excipient classification gradient maps","volume":"24","author":"Avdeef","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2015.12.018_bb0035","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejps.2007.09.009","article-title":"Absorption-excipient-pH classification gradient maps: sparingly soluble drugs and the pH partition hypothesis","volume":"33","author":"Avdeef","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.12.018_bb0040","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1007\/s11095-006-9137-8","article-title":"PAMPA excipient classification map","volume":"23","author":"Bendels","year":"2006","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2015.12.018_bb0045","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1007\/s11095-004-7675-5","article-title":"Effect of pluronic P85 on ATPase activity of drug efflux transporters","volume":"21","author":"Batrakova","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2015.12.018_bb0050","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.ejpb.2012.04.007","article-title":"Chitosan based drug delivery systems","volume":"81","author":"Bernkop-Schnurch","year":"2012","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb0055","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijpharm.2012.11.026","article-title":"Evaluation of gastrointestinal drug supersaturation and precipitation: strategies and issues","volume":"453","author":"Bevernage","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb0060","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1002\/jps.21650","article-title":"Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability","volume":"98","author":"Brouwers","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.12.018_bb0065","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.addr.2007.08.017","article-title":"The effects of pharmaceutical drug disposition","volume":"59","author":"Buggins","year":"2007","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2015.12.018_bb0070","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.2042-7158.1993.tb05548.x","article-title":"A modification of the extended Hildebrand approach to predict the solubility of structurally related drugs in solvent mixtures","volume":"45","author":"Bustamante","year":"1993","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2015.12.018_bb0075","doi-asserted-by":"crossref","first-page":"4940","DOI":"10.1002\/jps.22217","article-title":"The developability classification system: application of biopharmaceutics concepts to formulation development","volume":"99","author":"Butler","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.12.018_bb0080","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ijpharm.2015.08.002","article-title":"Towards a rational selection of excipients: excipient efficiency for controlled release","volume":"494","author":"Casas","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb0085","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.fluid.2010.09.025","article-title":"Solubility calculations of pharmaceutical compounds \u2014 a priori parameter estimation using quantum-chemistry","volume":"299","author":"Cassens","year":"2010","journal-title":"Fluid Phase Equilib."},{"key":"10.1016\/j.ejps.2015.12.018_bb0090","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0009-9236(96)80007-5","article-title":"The effect of water soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers","volume":"59","author":"Chang","year":"1996","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2015.12.018_bb0095","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1021\/cg060742p","article-title":"Cocrystals of piroxicam with carboxylic acids","volume":"7","author":"Childs","year":"2007","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejps.2015.12.018_bb0100","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1021\/cg801056c","article-title":"Analysis of 50 crystal structures containing carbamezapine using the materials module of mercury CSD","volume":"9","author":"Childs","year":"2009","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejps.2015.12.018_bb0105","series-title":"Concept Paper on the Need for Revision of the Guideline on Excipients in the Label and Package Leaflet of Medicinal Products for Human Use (CPMP\/463\/00)","author":"CPMP","year":"2012"},{"key":"10.1016\/j.ejps.2015.12.018_bb0110","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/jps.24299","article-title":"Excipient variability and its impact on dosage form functionality","volume":"104","author":"Dave","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.12.018_bb0115","first-page":"11","article-title":"The safety of pharmaceutical excipients","volume":"54","author":"De Jong","year":"1999","journal-title":"Therapie"},{"key":"10.1016\/j.ejps.2015.12.018_bb0120","first-page":"377","article-title":"Drug metabolism: manipulating the microbiome","volume":"294","author":"Deweerdt","year":"2015","journal-title":"Pharm. J."},{"key":"10.1016\/j.ejps.2015.12.018_bb0125","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1021\/ie101373k","article-title":"Solubility calculation of active pharmaceutical ingredients in alkanes, alcohols, water and their mixtures using various activity coefficient models","volume":"50","author":"Diedrichs","year":"2011","journal-title":"Ind. Eng. Chem. Res."},{"key":"10.1016\/j.ejps.2015.12.018_bb0130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijpharm.2012.10.041","article-title":"Aqueous solubility: simple predictive methods (in silico, in vitro and bio-relevant approaches)","volume":"453","author":"Elder","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb0135","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/jphp.12293","article-title":"The solid-state continuum: a perspective on the interrelationships between different solid-state forms in drug substance and drug product","volume":"67","author":"Elder","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2015.12.018_bb0140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ijpharm.2011.12.039","article-title":"Therapeutic antibodies: market considerations, disease targets and bioprocessing","volume":"440","author":"Elvin","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb0145","series-title":"Note for guidance on inclusion of antioxidants and antimicrobial preservatives in medicinal products","author":"EMA","year":"1997"},{"key":"10.1016\/j.ejps.2015.12.018_bb0150","series-title":"Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product","author":"EMA","year":"2007"},{"key":"10.1016\/j.ejps.2015.12.018_bb0155","series-title":"Guideline on the specification limits for residues of metal catalysts","author":"EMA","year":"2007"},{"key":"10.1016\/j.ejps.2015.12.018_bb0160","series-title":"Guideline on the investigation on bioequivalence","author":"EMA","year":"2010"},{"key":"10.1016\/j.ejps.2015.12.018_bb0165","series-title":"Appendix IV of the Guideline on the investigation on bioequivalence (CPMP\/EWP\/QWP\/1401\/98 Rev.1): presentation of biopharmaceutical and bioanalytical data in Module 2.7.1","author":"EMA","year":"2011"},{"key":"10.1016\/j.ejps.2015.12.018_bb0170","series-title":"Questions and answers on benzyl alcohol in the context of the revision of the guideline on \u2018Excipients in the label and package leaflet of medicinal products for human use\u2019 (CPMP\/463\/00)","author":"EMA","year":"2014"},{"key":"10.1016\/j.ejps.2015.12.018_bb0175","series-title":"Questions and answers on benzoic acid in the context of the revision of the guideline on \u2018Excipients in the label and package leaflet of medicinal products for human use\u2019 (CPMP\/463\/00)","author":"EMA","year":"2014"},{"key":"10.1016\/j.ejps.2015.12.018_bb0180","series-title":"Questions and answers on benzalkonium chloride in the context of the revision of the guideline on \u2018Excipients in the label and package leaflet of medicinal products for human use\u2019 (CPMP\/463\/00)","author":"EMA","year":"2014"},{"key":"10.1016\/j.ejps.2015.12.018_bb0185","series-title":"Questions and answers on ethanol in the context of the revision of the guideline on \u2018Excipients in the label and package leaflet of medicinal products for human use\u2019 (CPMP\/463\/00)","author":"EMA","year":"2014"},{"key":"10.1016\/j.ejps.2015.12.018_bb0190","series-title":"Questions and answers on propylene glycol and esters in the context of the revision of the guideline on \u2018Excipients in the label and package leaflet of medicinal products for human use\u2019 (CPMP\/463\/00 Rev.1)","author":"EMA","year":"2014"},{"key":"10.1016\/j.ejps.2015.12.018_bb0195","series-title":"Questions and answers on benzoic acid in the context of the revision of the guideline on \u2018Excipients in the label and package leaflet of medicinal products for human use\u2019 (CPMP\/463\/00 Rev. 1)","author":"EMA","year":"2014"},{"key":"10.1016\/j.ejps.2015.12.018_bb0200","series-title":"Questions and answers on cyclodextrins in the context of the revision of the guideline on \u2018Excipients in the label and package leaflet of medicinal products for human use\u2019 (CPMP\/463\/00 Rev. 1)","author":"EMA","year":"2014"},{"key":"10.1016\/j.ejps.2015.12.018_bb0205","series-title":"Background review for the excipient propylene glycol","author":"EMA","year":"2013"},{"key":"10.1016\/j.ejps.2015.12.018_bb0210","series-title":"Background review for cyclodextrins used as excipients","author":"EMA","year":"2014"},{"key":"10.1016\/j.ejps.2015.12.018_bb0215","series-title":"Reflection paper on the use of cocrystals and other solid 5 state forms of active substances in medicinal products","author":"EMA","year":"2014"},{"key":"10.1016\/j.ejps.2015.12.018_bb0220","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1021\/mp3001815","article-title":"Pharmaceutical excipients influence the function of human uptake transporting proteins","volume":"9","author":"Engel","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb0225","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1211\/jpp.59.8.0001","article-title":"Developing paediatric medicines: identifying the needs and recognising the challenges","volume":"59","author":"Ernest","year":"2007","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2015.12.018_bb0230","series-title":"Conference Proceedings. Nice, France, May 14\u201315, 1998","author":"EU ENTR\/F2\/BL D","year":"2003"},{"key":"10.1016\/j.ejps.2015.12.018_bb0235","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.phrs.2011.01.006","article-title":"Peadiatric pharmacology: remember the excipients","volume":"63","author":"Fabiano","year":"2011","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejps.2015.12.018_bb0245","author":"FDA"},{"key":"10.1016\/j.ejps.2015.12.018_bb0250","series-title":"Guidance for industry: regulatory classification of cocrystals","author":"FDA","year":"2013"},{"key":"10.1016\/j.ejps.2015.12.018_bb0255","series-title":"Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Guidance for Industry","author":"FDA","year":"2015"},{"key":"10.1016\/j.ejps.2015.12.018_bb0260","series-title":"FAQs on Avicel for solid dosage forms","author":"FMC biopolymer","year":"2015"},{"key":"10.1016\/j.ejps.2015.12.018_bb0265","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0378-5173(01)00801-8","article-title":"Selection of excipients for melt extrusion with two poorly water-soluble drugs by solubility parameter calculation and thermal analysis","volume":"226","author":"Forster","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb0270","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejpb.2015.05.015","article-title":"Advances in the design of fasted state simulating intestinal fluids: FaSSIF-V3","volume":"94","author":"Fuchs","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb0275","series-title":"Drug Delivery to the Brain","article-title":"Development of new protein vectors for the physiological delivery of large therapeutic compounds to the CNS","author":"Gabathuler","year":"2014"},{"issue":"5","key":"10.1016\/j.ejps.2015.12.018_bb0280","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1023\/A:1011910801212","article-title":"Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs","volume":"15","author":"Galia","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2015.12.018_bb0285","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijpharm.2012.09.027","article-title":"Coformer selection based on degradation pathway of drugs: a case study of adefovir dipivoxil\u2013saccharin and adefovir dipivoxil\u2013nicotinamide cocrystals","volume":"438","author":"Gao","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb0290","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejps.2014.09.004","article-title":"Interactions between active pharmaceutical ingredients and excipients affecting bioavailability: impact on bioequivalence","volume":"65","author":"Garcia-Arieta","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.12.018_bb0295","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ijpharm.2010.04.019","article-title":"The effects of excipients on transporter mediated absorption","volume":"393","author":"Goole","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb0300","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1021\/ie0003887","article-title":"Pertubated-chain SAFT: an equation of state based on a perturbation theory for chain molecules","volume":"40","author":"Gross","year":"2001","journal-title":"Ind. Eng. Res."},{"key":"10.1016\/j.ejps.2015.12.018_bb0305","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3109\/10837450903262041","article-title":"Comparative evaluation of the powder and compression properties of various grades and brands of microcrystalline cellulose by multivariate methods","volume":"15","author":"Haware","year":"2010","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejps.2015.12.018_bb0310","series-title":"The International Pharmaceutical Excipients Council Meeting","article-title":"Addressing specific regulatory excipient requirements in the marketing authorization","author":"Hebestreit","year":"2009"},{"key":"10.1016\/j.ejps.2015.12.018_bb0315","series-title":"14th Biannual Congress of the European Society for the Development of Perinatal and Paediatric Pharmacology (ESDPPP), Salzburg Austria","article-title":"Circulating ethanol levels in neonates administered clinically indicated medications: feasibility of microsampling methods as part of European study of neonatal exposure to excipients","author":"Hubbard","year":"2013"},{"key":"10.1016\/j.ejps.2015.12.018_bb9020","article-title":"Validation of analytical procedures: Text and methodology","author":"ICH Q2 (R1)","year":"2005","journal-title":"Current step 4 (November 2005)"},{"key":"10.1016\/j.ejps.2015.12.018_bb9030","series-title":"Pharmaceutical development","author":"ICH Q8 (R2)","year":"2009"},{"key":"10.1016\/j.ejps.2015.12.018_bb0325","series-title":"Guideline for elemental impurities","author":"ICH Q3D","year":"2014"},{"key":"10.1016\/j.ejps.2015.12.018_bb0330","series-title":"Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk","author":"ICH M7","year":"2014"},{"key":"10.1016\/j.ejps.2015.12.018_bb9015","series-title":"Excipients in pharmaceutical dosage forms: The challenge of the 21st century","author":"IPEC","year":"1998"},{"key":"10.1016\/j.ejps.2015.12.018_bb0335","article-title":"A novel approach for analyzing the dissolution mechanism of solid dispersions","volume":"2015","author":"Ji","year":"2015","journal-title":"Pharm. Res."},{"issue":"2","key":"10.1016\/j.ejps.2015.12.018_bb8900","first-page":"113","article-title":"Deviations of drug solubility in water-cosolvent mixtures from the Jouyban-Acree model--effect of solute structure","volume":"63","author":"Jouyban","year":"2008","journal-title":"Pharmazie"},{"key":"10.1016\/j.ejps.2015.12.018_bb0340","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1021\/jm970530e","article-title":"Physicochemical high throughput screening: parallel artificial membrane permeability assay in the description of passive absorption processes","volume":"41","author":"Kansy","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2015.12.018_bb0345","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ddtec.2004.11.013","article-title":"Advances in screening for membrane permeability: high-resolution PAMPA for medicinal chemists","volume":"1","author":"Kansy","year":"2004","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2015.12.018_bb0350","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.addr.2011.10.009","article-title":"Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs","volume":"64","author":"Kawakami","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2015.12.018_bb0355","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.drudis.2011.05.010","article-title":"Pharmaceutical drug transport: the issue and the implications that it is essentially carrier-mediated only","volume":"16","author":"Kell","year":"2011","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejps.2015.12.018_bb0360","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1021\/j100007a062","article-title":"Conductor-like screening model for real solvents: a new approach to the quantitative calculation of solvation phenomena","volume":"99","author":"Klamt","year":"1995","journal-title":"J. Phys. Chem."},{"key":"10.1016\/j.ejps.2015.12.018_bb0365","series-title":"Study of Standardized Taurocholate\u2013Lecithin Powder for Preparing the Biorelevant Media FeSSIF and FaSSIF","first-page":"6","author":"Kloefer","year":"2010"},{"key":"10.1016\/j.ejps.2015.12.018_bb0370","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejps.2013.09.008","article-title":"PBPK models for the prediction of in vivo performance of oral dosage forms","volume":"57","author":"Kostewicz","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.12.018_bb0375","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/bi035768l","article-title":"Ionophoric activity of pluronic block copolymers","volume":"43","author":"Krylova","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejps.2015.12.018_bb0380","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejps.2014.03.008","article-title":"Novel insights into excipient effects on the biopharmaceutics of APIs from different BCS classes: lactose in solid oral dosage forms","volume":"61","author":"Kubbinga","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.12.018_bb0385","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1208\/s12248-008-9054-3","article-title":"Drug absorption modelling as a tool to define the strategy in clinical formulation development","volume":"10","author":"Kuentz","year":"2008","journal-title":"AAPS J."},{"key":"10.1016\/j.ejps.2015.12.018_bb0390","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/jphp.12271","article-title":"Analytical technologies for real-time drug dissolution and precipitation testing on a small scale","volume":"67","author":"Kuentz","year":"2014","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2015.12.018_bb0395","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3109\/03639049209043705","article-title":"Comparison of two varieties of microcrystalline cellulose as filler-binders. I. Prednisolone tablets","volume":"18","author":"Landin","year":"1992","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb0400","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability and permeability in drug discovery and developmental settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2015.12.018_bb0405","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1021\/mp400175n","article-title":"Mediation of in vitro cyctochrome P450 activity by common pharmaceutical excipients","volume":"10","author":"Martin","year":"2013","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb0410","series-title":"Overview of the Pharmacopoeial Discussion Group: harmonization from a compendial perspective","author":"Moore","year":"2014"},{"key":"10.1016\/j.ejps.2015.12.018_bb0415","series-title":"Encyclopedia of Pharmaceutical Science and Technology","article-title":"Excipients: parenteral dosage forms and their role","author":"Nema","year":"2013"},{"key":"10.1016\/j.ejps.2015.12.018_bb0420","article-title":"The effect of excipients on the permeability of BCS CLASS III compounds and implications for biowaivers","author":"Parr","year":"2015","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2015.12.018_bb0425","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijpharm.2015.03.004","article-title":"Influence of excipients on solubility and dissolution of pharmaceuticals","volume":"485","author":"Paus","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb0430","series-title":"PhRMA Statement Regarding Drug Shortages","year":"2011"},{"key":"10.1016\/j.ejps.2015.12.018_bb0435","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1021\/mp400729x","article-title":"Thermodynamic phase behavior of API\/polymer solid dispersions","volume":"11","author":"Prudic","year":"2014","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb0440","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ejps.2013.04.021","article-title":"Application of COSMOS-RS as an excipient ranking tool in early formulation development","volume":"49","author":"Pozarska","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.12.018_bb0445","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1021\/js960075u","article-title":"Pharmaceutical applications of cyclodextrins 2. In vivo drug delivery","volume":"85","author":"Rajewski","year":"1996","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.12.018_bb0450","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/jps.1127","article-title":"Effect of common excipients on CaCo-2 transport of low permeability drugs","volume":"90","author":"Rege","year":"2001","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.12.018_bb0455","first-page":"279","article-title":"Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration","volume":"70","author":"Ren","year":"2008","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.12.018_bb0460","series-title":"Shin-Etsu cellulose plant hit by explosion, fire","author":"Reuters","year":"2007"},{"key":"10.1016\/j.ejps.2015.12.018_bb0465","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1081\/DDC-120003448","volume":"28","author":"Rostami-Hodjegan","year":"2002","journal-title":"Drug. Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb0470","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1081\/DDC-120003449","article-title":"A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. II. Dissolution studies and in vitro\/in vivo correlation","volume":"28","author":"Rostami-Hodjegan","year":"2002","journal-title":"Drug. Dev. Ind. Pharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb9010","series-title":"Handbook of pharmaceutical excipients","author":"Rowe","year":"2012"},{"key":"10.1016\/j.ejps.2015.12.018_bb0475","first-page":"38","article-title":"Synthetic excipients challenge all natural organics \u2014 offer advantages\/challenges to developers and formulators","volume":"27","author":"Russell","year":"2004","journal-title":"Pharm. Technol."},{"key":"10.1016\/j.ejps.2015.12.018_bb0480","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijpharm.2012.05.004","article-title":"The STEP (safety and toxicity of excipients for paediatrics) database. Part 1\u2014a need assessment study","volume":"435","author":"Salunke","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb0485","series-title":"ExcipientFest Asia, 25th\u201326th March 2015, Renaissance Shanghai Zhongshan Park Hotel, China","article-title":"ICH Q3D: elemental Impurities \u2014 how to prepare your company to comply with the regulations","author":"Schonecker","year":"2015"},{"issue":"7","key":"10.1016\/j.ejps.2015.12.018_bb9005","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1021\/js980434g","article-title":"Selection of solid dosage form composition through drug \u2014 excipient comaptibility testing","volume":"88","author":"Serajuddin","year":"1999","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.12.018_bb0490","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.fluid.2010.08.029","article-title":"Thermodynamics of pharmaceuticals: prediction of solubility in pure and mixed solvents with PC-SAFT","volume":"302","author":"Spyriouni","year":"2011","journal-title":"Fluid Phase Equilib."},{"key":"10.1016\/j.ejps.2015.12.018_bb0495","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ejps.2007.05.110","article-title":"When poor solubility becomes an issue: from early stage to proof of concept","volume":"31","author":"Stegemann","year":"2007","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2015.12.018_bb0500","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1006\/rtph.1996.0120","article-title":"A new approach to the safety assessment of pharmaceutical excipiens. The safety committee of the international pharmaceutical excipient council","volume":"24","author":"Steinberg","year":"1996","journal-title":"Regul. Toxicol. Pharmacol."},{"key":"10.1016\/j.ejps.2015.12.018_bb0505","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1023\/B:PHAM.0000016235.32639.23","article-title":"Solubilizing excipients in oral and injectable formulations","volume":"21","author":"Strickley","year":"2004","journal-title":"Pharm. Res."},{"issue":"3","key":"10.1016\/j.ejps.2015.12.018_bb0510","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/108705710100600309","article-title":"High throughput prediction of oral absorption: improvement of the composition of the lipid solution used in parallel artificial membrane permeability assay","volume":"6","author":"Sugano","year":"2001","journal-title":"J. Biomol. Screen."},{"key":"10.1016\/j.ejps.2015.12.018_bb0515","series-title":"Guidance for Industry. Immediate Release Solid Oral Dosage Forms Scale-up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation","author":"SUPAC IR","year":"1995"},{"key":"10.1016\/j.ejps.2015.12.018_bb0520","series-title":"Guidance for Industry. Nonsterile Semisolid Dosage Forms. Scale-up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation","author":"SUPAC SS","year":"1997"},{"key":"10.1016\/j.ejps.2015.12.018_bb0525","series-title":"Guidance for Industry SUPAC-MR: Modified Release Solid Oral Dosage Forms Scale-up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation","author":"SUPAC MR","year":"1997"},{"key":"10.1016\/j.ejps.2015.12.018_bb0530","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0009-9236(03)00059-6","article-title":"Pharmacokinetic and pharmaceutic interaction between digoxin and cremophor RH40","volume":"73","author":"Tayrouz","year":"2003","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2015.12.018_bb0535","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijpharm.2006.04.018","article-title":"Physical stability enhancement of theophylline by cocrystallization","volume":"320","author":"Trask","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb0540","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ijpharm.2013.08.078","article-title":"European study of neonatal exposure to excipients: an update","volume":"437","author":"Turner","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2015.12.018_bb0545","series-title":"14th Biannual Congress of the European Society for the Development of Perinatal and Paediatric Pharmacology (ESDPPP), Salzburg Austria","article-title":"Methyl and propyl paraben blood concentrations in blood from preterm neonates exposed to clinically indicated medicines are lower than the concentrations of these anti-microbial excipients reported to affect cell physiology","author":"Turner","year":"2013"},{"key":"10.1016\/j.ejps.2015.12.018_bb0550","unstructured":"USP. Excipient Biological Safety Evaluation Guidelines <1074>."},{"key":"10.1016\/j.ejps.2015.12.018_bb0555","series-title":"Good manufacturing practices for bulk pharmaceutical excipients. <1078>","author":"USP","year":"2015"},{"issue":"4","key":"10.1016\/j.ejps.2015.12.018_bb9000","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jpba.2005.02.026","article-title":"Selection of excipients for extended release fornulations of glipizide throgh drug-excipient compatibility testing","volume":"38","author":"Verma","year":"2005","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejps.2015.12.018_bb0560","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1211\/0022357022935","article-title":"Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects","volume":"56","author":"Vertzoni","year":"2004","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejps.2015.12.018_bb0565","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0169-409X(01)00183-1","article-title":"Intestinal drug efflux: formulation and food effects","volume":"50","author":"Wagner","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejps.2015.12.018_bb0570","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3109\/1061186X.2010.525652","article-title":"Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: a mechanistic basis for utility","volume":"18","author":"Warren","year":"2010","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejps.2015.12.018_bb0575","series-title":"Proposal to Waive in Vivo Bioequivalence Requirements for WHO Model List of Essential Medicines Immediate Release, Solid Oral Dosage Forms","article-title":"WHO Technical Report Series, No. 937. Annex 8","author":"WHO","year":"2006"},{"key":"10.1016\/j.ejps.2015.12.018_bb0580","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1007\/s11095-006-9205-0","article-title":"Miniaturized assay for solubility and residual solid state screening (SORESOS) in early drug development","volume":"24","author":"Wyttenbach","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2015.12.018_bb0585","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2007.08.021","article-title":"Effect of excipients on breast cancer resistant protein substrate uptake activity","volume":"124","author":"Yamagata","year":"2007","journal-title":"J. Control. Release"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098715300920?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098715300920?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,16]],"date-time":"2018-09-16T17:54:59Z","timestamp":1537120499000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098715300920"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":123,"alternative-id":["S0928098715300920"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2015.12.018","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmaceutical excipients \u2014 quality, regulatory and biopharmaceutical considerations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2015.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}